About S100P-binding protein
S100P-binding protein (S100PBP) is a protein
from Homo sapiens identified by UniProt accession
Q96BU1, 408 residues long.
MolForge cross-references it against 0 known binders and
29 disease associations.
Target properties
| Protein name | S100P-binding protein |
| UniProt accession | Q96BU1 |
| Gene | S100PBP |
| Organism | Homo sapiens |
| Length | 408 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (29)
Diseases linked to this target (Open Targets).
- neurologic, endocrine, and pancreatic disease, multisystem, infantile-onset · score 0.27
- Charcot-Marie-Tooth disease dominant intermediate C · score 0.19
- body mass index · score 0.15
- daytime rest measurement · score 0.12
- genetic disorder · score 0.12
- excessive daytime sleepiness measurement · score 0.12
- visceral adipose tissue measurement · score 0.11
- body height · score 0.10
- lean body mass · score 0.09
- body weight · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96BU1-F1 | alphafold | PREDICTED | 53.85 | — |
Amino-acid sequence (408 residues)
MMCSRVPSEQ SSGTSLLPKD GAPFSWDSLD EDGLDDSLLE LSEGEEDDGD VNYTEEEIDA LLKEDDPSYE QSSGEDDGGH VEKGERGSQI LLDTPREKNS SYSLGPVAET PDLFKLPQLS TSSGHGPAHT KPLNRRSVLE KNLIKVTVAP FNPTVCDALL DKDETDSSKD TEKLSSLGEE MREDGLSPNE SKLCTESEGI SPNNSAWNGP QLSSSNNNFQ QTVSDKNMPD SENPTSVFSR ISDHSETPNM ELSCRNGGSH KSSCEMRSLV VSTSSNKQDV LNKDSGKMKG HERRLGKVIP VLQTKTRTNV PTFSQSNLEQ QKQLYLRSVI AHIEDPEDTN QGISGELCAL MDQVHHMQHS KWQHPSDLTT RNYARRQKHL QRYSLTQWVD RNMRSHHRFQ RLPDFSYS
Explore S100P-binding protein with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets